Overview of sample numbers in each subject group, treatment arm, sampling time point and response group
CTX participants | HSCT participants | All SSc | |||||
Death/organ failure | Survived event-free | Total CTX | Death/organ failure | Survived event-free | Total HSCT | Total | |
No of participants | 15 | 17 | 32 | 6 | 25 | 31 | 63 |
Time point | CTX time points | HSCT time points | All SSc time points | ||||
Death/organ failure | Survived event-free | Total CTX | Death/Organ failure | Survived event-free | Total HSCT | Total (per time point) | |
Baseline | 15 | 17 | 32 | 6 | 25 | 31 | 63 |
T1m | 0 | 0 | 0 | 1 | 0 | 1 | 1 |
T14m | 4 | 0 | 4 | 3 | 0 | 3 | 7 |
T20m | 3 | 0 | 3 | 1 | 0 | 1 | 4 |
T26m | 8 | 14 | 22 | 1 | 22 | 23 | 45 |
T38m | 4 | 12 | 16 | 0 | 21 | 21 | 37 |
T44m | 1 | 0 | 1 | 0 | 0 | 0 | 1 |
T48m | 0 | 11 | 11 | 0 | 19 | 19 | 30 |
T54m | 0 | 1 | 1 | 0 | 3 | 3 | 4 |
Total | 35 | 55 | 90 | 12 | 90 | 102 | 192 |
A total of 192 serum samples from 63 SCOT participants were available. The table provides a detailed overview of sample numbers per time point for each treatment arm.
CTX, cyclophosphamide; HSCT, haematopoietic stem cell transplant; SCOT, haematopoietic stem cell transplant; SSc, systemic sclerosis.